The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Improving second-line treatments in DLBCL
Keith Wilson, MBBS, FRCP, FRCPath, Cardiff University, Cardiff and Vale University Health Board, Cardiff, Wales, briefly explains the need to improve second-line treatment options for patients with diffuse large B-cell lymphoma (DLBCL). Dr Wilson first discusses the role of transplantation as a second-line therapy, and then emphasizes the need to improve options for patients who relapse or do not respond. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
